Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2006-04-18
2006-04-18
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S649000, C514S492000
Reexamination Certificate
active
07029696
ABSTRACT:
Antitumor compositions are disclosed, as well as methods of preparing the compositions and methods of using them to inhibit tumor growth in mammals. The invention can take advantage of intraliposomal conversion of a platinum complex having the formulawhere R1is diaminocycloalkyl, and R2and R3each have the formulawhere R4, R5, and R6are each independently hydrocarbon moieties having from 1 to about 10 carbon atoms,into a complex having the formulain-line-formulae description="In-line Formulae" end="lead"?R1—Pt—X2 (II)in-line-formulae description="In-line Formulae" end="tail"?where X is halogen.
REFERENCES:
patent: 3904663 (1975-09-01), Tobe et al.
patent: 4169846 (1979-10-01), Kidani et al.
patent: 4200583 (1980-04-01), Kidani et al.
patent: 4203912 (1980-05-01), Hydes et al.
patent: 4230631 (1980-10-01), Hydes et al.
patent: 4255347 (1981-03-01), Kidani et al.
patent: 4256652 (1981-03-01), Kidani et al.
patent: 4431666 (1984-02-01), Bulten et al.
patent: 4466924 (1984-08-01), Verbeek et al.
patent: 4661516 (1987-04-01), Brown et al.
patent: 4758588 (1988-07-01), Brown et al.
patent: 4760155 (1988-07-01), Heffernan et al.
patent: 4760157 (1988-07-01), Child et al.
patent: 4845124 (1989-07-01), Kidani et al.
patent: 4861905 (1989-08-01), Nowatari et al.
patent: 4946954 (1990-08-01), Talebian et al.
patent: 4956459 (1990-09-01), Talebian et al.
patent: 5011959 (1991-04-01), Khokhar et al.
patent: 5041578 (1991-08-01), Khokhar
patent: 5041581 (1991-08-01), Khokhar et al.
patent: 5117022 (1992-05-01), Khokhar et al.
patent: 5178876 (1993-01-01), Khokhar et al.
patent: 5186940 (1993-02-01), Khokhar et al.
patent: 5384127 (1995-01-01), Perez-Soler et al.
patent: 5422364 (1995-06-01), Nicolau
patent: 5843475 (1998-12-01), Perez-Soler et al.
patent: 6613799 (2003-09-01), Maeda et al.
patent: 6696079 (2004-02-01), Perez-Soler et al.
patent: 0113508 (1984-07-01), None
patent: 0136012 (1985-04-01), None
patent: 0147926 (1985-07-01), None
patent: 0237450 (1987-09-01), None
patent: 0193936 (1989-05-01), None
patent: 0356332 (1990-02-01), None
patent: 0130482 (1995-01-01), None
patent: WO 87/02364 (1987-04-01), None
patent: WO 88/03925 (1988-06-01), None
patent: WO 90/02131 (1990-03-01), None
Connors, T.A. et al, “New Platinum Complexes with Anti-Tumor Activity”Chem.-Biol. Interactions. 5:415-424 (1972).
Craciunescu, D.G. et al, “On the preparation, antitumour and cytotoxic evaluation of some new analogues of the cis-dichloro (1,2-diamino-cyclohexane) platinum (II) complex”, Eur. J. Med. Chem.-Chem. Ther., 19:353-357 (1984).
Deliconstantinos, G. et al, “Incorporation of Cis-Dichlorobiscyclopentylamineplatinum (II) into Liposomes Enhances its Uptake by Adj-PC6A Tumours Implanted Subcutaneously into Mice”, Abstract from Biochem. Soc. Trans., 5(5):1326-1328(1977).
Freise, J. et al, “Pharmacokinetics of Liposome Encapsulated Cisplatin in Rats”, Archies Internationales de Pharmacodynamie et de Therapie, 258(2):180-192 (Aug. 1982).
Han et al., 1996, “Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R,R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R,R-1, 2-diaminocyclohexane-platinum (II)”, Cancer Chemother. Pharmacol. 39:17-24.
Han et al., Cellular pharmacolocy of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res. 53:4913-19, 1993.
Han et al., Intraliposomal conversion of lipophilic 1,2-DACH-bisalkyl-platinum(II) complexes into DACH-Pt-Cl.sub.2 (II). Proceed AACR 37:2740 p. 401,1996.
Han et al., Liposomal-platinum (II) compounds (L-Pt): optimization of formulation parameters. Proceed AACR 35:2482 p. 416., 1994.
Hollis et al., cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents. J Med Chem. 33:105-11, 1990.
Ismail et al., .sup.195 Pt- and .sup.15 N-NMR studies of antitumor complexes. ACS Symposium Series, 209:171-190, 1983.
Kaledin, V. et al, “Intralymphatic Administration of Liposome-Encapsulated Drugs to Mice: Possibility for Suppression of the Growth of Tumor Metastases in the Lymph Nodes”, Jncl. 66(5):881-886 (May 1981).
Khokhar et al., Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -S,S)-1,2-Diaminocyclohexane) Platinum(II) Complexs Incorporated in Liposomes. J. Med. Chem. 34:325-329, 1991.
Khokhar et al., Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Cancer Chemother Pharmacol. 23:219-24, 1989.
Khokhar et al., Toxicity and efficacy studies on a series of lipid-soluble dineodecnoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes. Anticancer Drugs. 3:95-100, 1992.
Khokhar, A.R. et al, “The Synthesis and Antitumor Properties of a Series of Water Soluble carboxylato-(1,2-diaminocyclohexane) Platinum(ll) Complexes”, Inorganica chimica Acta, 108(1):63-66 (Sep. 1985).
Li et al., Improved antitumor activity of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) entrapped in long-circulating liposomes. Oncology Res. 7:611-17, 1995.
Mori et al., In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol. 37:435-44, 1996.
Perez-Soler et al., Clinical development of Liposomal Platinum. J Lip Res. 1:437-449, 1990.
Perez-Soler et al., Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecnoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. Cancer Res. 48:4509-12, 1988.
Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res. 52:6341-47, 1992.
Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of chemical structure and liposome composition. Proceed AACR 32:2425 p. 408, 1991.
Perez-Soler et al., Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups. cancer Chemother Pharmacol. 33:378-84, 1994.
Perez-Soler et al., Lipophilic platinum compounds entrapped on liposomes: enhanced intraliposomal stability and preserved antitumor activity by using analogs with linear aliphatic leaving groups. Proceed AACR. 34:2182 p. 366, 1993.
Perez-Soler et al., Liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP): effect of lipid composition on biological activity. Proceed AACR. 31:2542 p. 428, 1990.
Perez-Soler, et al, “Phase I Clinical and Pharmacological Study of Liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane Platinum(II)”, Cancer Research, 50(14):4254-4259 (Jul. 1990).
Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2,5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264., 1990.
Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2.5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264., 1990.
Qu et al., Interaction of bis(platinum) complexes with the mononucleotide 5'-guanosine monophosphate. Effect of diamine linker and the nature of the bis(platinum) complex of product formation. J. Am. Chem. Soc. 113:4851-4857, 1991.
Ridgway, H.J. et al, “Analogs of Sulfato 1,2-Diaminocyclohexane Platinum(II) I Modifications in Leaving Ligand”, Wadley Medical Bulletin, 7(1):220,229 (1977).
Schwartz, P. et al, “Preparation and Antitumor Evaluation of Water-Soluble Derivatives of Dichloro(1,2-diaminocyclohexane)platinum(II)”, Cancer Treatment Reports, 61(8):1519-1525 (Nov., 1997).
Slavin et al
Khokhar Abdul R.
Perez-Soler Roman
Board of Regents , The University of Texas System
Jones Day
Kishore Gollamudi S.
LandOfFree
Delivery and activation through liposome incorporation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery and activation through liposome incorporation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery and activation through liposome incorporation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3593669